HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $20

HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $15 to $20.